Patient Test Information


  • Why Get Tested?

    To help evaluate insulin production by the beta cells in the pancreas or to help determine the cause of low blood glucose (hypoglycemia)

    When To Get Tested?

    When you have diabetes and your health practitioner wants to determine if you are producing enough of your own insulin or there is an absolute need for insulin injections or an insulin pump; when your health practitioner suspects that you have insulin resistance or your diabetes has been incorrectly classified; when you have documented hypoglycemia and your health practitioner is investigating causes.

    Sample Required?

    A blood sample is obtained by inserting a needle into a vein. If a 24-hour urine sample is required, all urine produced over a 24-hour time period will be collected.

    Test Preparation Needed?

    Fasting for 8 to 10 hours before blood testing is usually required. In some cases, your healthcare practitioner may want to examine C-peptide production after a formal stimulation test in which you will be administered a standardized amount of a meal or substance that stimulates the pancreas.

  • What is being tested?

    C-peptide is a substance, a short chain of amino acids, that is released into the blood as a byproduct of the formation of insulin by the pancreas. This test measures the amount of C-peptide in a blood or sometimes a urine sample.

    In the pancreas, within specialized cells called beta cells, proinsulin, a biologically inactive molecule, is split apart to form one molecule of C-peptide and one molecule of insulin. Insulin is vital for the transport of glucose into the body's cells and is required on a daily basis. When insulin is released from the beta cells into the blood in response to increased levels of glucose, equal amounts of C-peptide are also released. Since C-peptide is produced at the same rate as insulin, it is useful as a marker of insulin production.

    In particular, C-peptide testing can be used to help evaluate the production of insulin made by the body (endogenous) and to help differentiate it from insulin taken in as diabetic medication (exogenous) which not generate C-peptide. This test may be done in conjunction with an insulin test or a glucose test.

  • How is the test used?

    While not a regularly ordered lab test, C-peptide testing can be very useful in certain medical situations. Additionally, with the rising incidence of type 2 diabetes in younger patients and newer medications aimed at preserving insulin production, the test will likely become more important.

    The following are some uses of C-peptide testing:

    • To evaluate the cause of documented hypoglycemia Symptoms of hypoglycemia may be caused by excessive supplementation of insulin, alcohol consumption, inherited liver enzyme deficiencies, liver or kidney disease, or by insulinomas. Insulinomas are tumors of the islet cells in the pancreas that can produce uncontrolled amounts of insulin and C-peptide and can cause acute episodes of hypoglycemia. • To monitor the effectiveness of insulinoma treatment and to detect its recurrence
    • To assist in management of people with diabetes treated with insulin. Most insulin tests are not able to distinguish between the body’s own insulin and that given by injections, but C-peptide levels reflect only the insulin being produced by the body’s own functioning beta cells. Additionally, people taking insulin may produce antibodies against insulin that could interfere with insulin testing, but not with C-peptide testing. Knowing how much C-peptide (and thus insulin) is being produced by the beta cells may allow healthcare practitioners to know when insulin is absolutely required and when it may be safe to switch to a different type of treatment.
    • To assist in classification of diabetes in select cases Generally, type 1 and type 2 diabetes will be classified without this test. However, with increased prevalence of obesity in teens and the understanding of other types of diabetes, some people with diabetes may be difficult to classify and/or classified incorrectly. Measurement of a C-peptide 3-5 years from diagnosis can assist in classification.
    • When you have had your pancreas removed or have had pancreas islet cell transplants, intended to restore the ability to make insulin, C-peptide levels may be used to verify the effectiveness of treatment and continued success of the procedure.

    When is it ordered?

    C-peptide levels may be ordered when there is documented acute or recurring low blood glucose (hypoglycemia) and/or excess insulin is suspected. C-peptide tests help distinguish the body's own insulin from outside sources of insulin. Symptoms of hypoglycemia include:

    • Sweating
    • Palpitations
    • Hunger
    • Confusion
    • Blurred vision
    • Fainting
    • In severe cases, seizures and loss of consciousness

    However, many of these symptoms can occur with other conditions as well. 

    A C-peptide test may be ordered periodically when you have been diagnosed with an insulinoma to monitor the effectiveness of treatment and to detect tumor recurrence.

    C-peptide levels may be ordered when the healthcare provider wishes to assess whether a person with diabetes still requires insulin injections or can switch to a different type of medication. This is more commonly part of the management of type 1 diabetes, but may be useful in knowing when patients with type 2 diabetes have developed an absolute insulin requirement. If a healthcare provider is suspecting incorrect classification of a person’s diabetes, the test may be ordered.

    Rarely, C-peptide levels may be monitored over time when you have had your pancreas removed or have had pancreas islet cell transplants.

    What does the test result mean?

    A high level of C-peptide generally indicates a high level of endogenous insulin production. This may be in response to a high blood glucose caused by glucose intake and/or insulin resistance. A high level of C-peptide is also seen with insulinomas and may be seen with low blood potassium, Cushing syndrome, and renal failure.

    A low level of C-peptide is associated with a low level of insulin production. This can occur when insufficient insulin is being produced by the beta cells, with diabetes for example, or when production is suppressed by treatment with exogenous insulin.

    Absent C-peptide means there is an absolute requirement for insulin from an outside source.

    When used for monitoring someone diagnosed with an insulinoma, decreasing levels of C-peptide indicate a response to treatment. Levels that increase may indicate that a tumor has come back (recurrence).

    When used for managing your diabetes, the meaning of a value must be considered in context of your type of diabetes and the type of treatment you are currently receiving. With all the information, your healthcare practitioner can determine whether or not a change in treatment is necessary.

    Is there anything else I should know?

    C-peptide testing has become more widely available, though there is still some method variability. If a series of C-peptide tests are going to be performed, they should be done at the same laboratory using the same method.

    Even though they are produced at the same rate, C-peptide and insulin leave the body by different routes. Insulin is processed and eliminated mostly by the liver, while C-peptide is removed by the kidneys. Since the half-life of C-peptide is longer than insulin, its levels in the blood are higher than insulin, making it a more reliable measure of insulin production.

    Can I do a C-peptide test at home like I can when I check my blood glucose?

    No. The C-peptide test requires special equipment and training to perform.

    If I need to go on the insulin pump, will I need a C-peptide test?

    You may. Insulin pumps may be desirable or recommended for certain people with diabetes who require regular insulin injections. Some insurance plans may require C-peptide results prior to approval of coverage for insulin pumps.

    What else is known about C-peptide?

    Researchers are starting to better understand the role of C-peptide in the body. Some studies have been conducted to evaluate the use of C-peptide in conjunction with insulin for those with diabetes. Results have been promising, showing decreased diabetic complications with improvements in kidney function, blood flow, and nerve function. However, further studies are needed.

  • View Sources

    Sources Used in Current Review

    Current review performed by Jennifer L. Powers, DABCC, Assistant Director, Core Lab for Clinical Studies, Washington University in St. Louis

    (April 2015) American Association of Clinical Endocrinologists/American College of Endocrinology Diabetes Guidelines. Accessed on 4/26/2017.

    (January 2017) American Diabetes Association Standards of Professional Care. Available at Accessed on 4/26/2017.

    (2011) International Diabetes Foundation IDF/ISPAD Guidelines. Accessed on 4/26/2017

    (February 14, 2013) Jones, AG and Hattersley, AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Accessed on 4/25/2017.

    Burtis, CA, and Bruns, DE, eds. Tietz Fundamentals of Clinical Chemistry, 7th ed. Saunders, 2015. pp. 615-616. NACB Recommendations 2011 Laboratory Medicine Practice Guidelines Accessed on 4/26/2017.

    (March 28, 2013) Centers for Medicare & Medicaid Services (CMS). Infusion Pumps: C-Peptide Levels as a Criterion for Use . Accessed on 4/25/2017.

    (April 2012) Wahren, J., Kallas, A., and Sima A. The clinical potential of C-peptide replacement in Type 1 Diabetes. Accessed on 4/25/2017.

    Sources Used in Previous Reviews

    Topiwala, S. (Updated 2012 June 4). Insulin C-peptide. MedlinePlus Medical Encyclopedia [On-line information]. Available online at Accessed December 2013.

    Elhomsy, G. (Updated 2012 September 7). C-Peptide. Medscape Reference [On-line information]. Available online at Accessed December 2013.

    (© 1995–2013). C-Peptide, Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at through. Accessed December 2013.

    Parkin, C. (2013 February). LADA, the Other Diabetes, Can Be Hard to Spot. Diabetes Forecast [On-line information]. Available online at Accessed December 2013.

    Weisenberger, J. (2013 March) Why Does a C-Peptide Test Matter? Diabetes Forecast [On-line information]. Available online at Accessed December 2013.

    Delgado, J. et. al. (Updated 2013 January). Hyperinsulinemic Hypoglycemia. ARUP Consult [On-line information]. Available online at Accessed December 2013.

    Son, S. (2012 October). C-Peptide and Vascular Complications in Type 2 Diabetic Subjects. Diabetes Metab J. v36 (5): 345–349. [On-line information]. Available online at Accessed December 2013.

    Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 317-318.

    Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. 4th edition, St. Louis: Elsevier Saunders; 2006, Pp 850-851.

    Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

    Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

    Torres, A. (2002 August 19, Updated). What is c-peptide? What do c-peptide levels mean?, diabetes FAQ [On-line information from newsgroup]. Available online at 

    Fish, S., Updated (2002 February 18, Updated). Insulin C-peptide. MEDLINEplus Health Information [On-line information]. Available online at

    Tunis, S., et. al. (2001 May 14). Insulin Pump: C-Peptide levels as a Criterion for Use. Center for Medicare & Medicaid Services, Medicare Coverage Policy, NCDs [On-line Decision Memorandum]. Available online at

    Liposcience. C-Peptide. Liposcience, Clinicians Testing Menu [On-line information]. Available online at

    CSU (1999 June 15, Updated). Insulin Synthesis and Secretion. Colorado State University, Pathophysiology of the Endocrine System [On-line Biomedical Hypertextbook]. Available online at 

    WSU (2001 Winter). Researchers gather for symposium on promising treatment for Type 1 diabetes. Wayne State University, Scribe [On-line Newsletter]. Available online at

    Warner, J. (2002 April 10). Extra Pounds Raise Breast Cancer Risk. WebMD [On-line Article]. Available online at

    Bell, D. (2001 December 1). Editorials, Combination Therapy for Type 2 Diabetes. AAFP, American Family Physician [On-line Journal]. Available online at

    ARUP. C-Peptide, Serum. ARUP's Guide to Clinical Laboratory Testing (CLT) [On-line Test Menu]. Available online at

    DPC. Clinical Applications of Insulin and C-Peptide Determinations. Diagnostic Products Corporation [On-line testing information]. Available online at

    Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. St. Louis, Missouri Elsevier Saunders; 2006.

    David B. Sacks, David E. Bruns, David E. Goldstein, Noel K. Maclaren, Jay M. McDonald, and Marian Parrott. GUIDELINES AND RECOMMENDATIONS FOR LABORATORY ANALYSIS IN THE DIAGNOSIS AND MANAGEMENT OF DIABETES MELLITUS (Online information, accessed November 2006). Available online through

    Wu, A. (2006). Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders Elsevier, St. Louis, Missouri. Pages 186-188.

    Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 314-315.

    Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 290-291.

    Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 186-189.

    Holt, E. (Updated 2008 June 17). Insulin C-peptide. MedlinePlus Medical Encyclopedia [On-line information]. Available online at Accessed December 2009.

    Dowshen, S. (Reviewed 2009 January) Blood Test: C-Peptide [On-line information]. Available online at Accessed December 2009.

    (© 1995-2009). Unit Code 8804: C-Peptide, Serum. Mayo Clinic, Mayo Medical Laboratories [On-line information]. Available online at Accessed December 2009.

    Hussain, A. N. and Vincent, M. (Updated 2009 July 2). Diabetes Mellitus, Type 1. eMedicine [On-line information]. Available online at Accessed December 2009.

    Ligaray, K. and Isley, W. (Updated 2009 October 28). Diabetes Mellitus, Type 2. eMedicine [On-line information]. Available online at Accessed December 2009.

    S9 (2008 November). Diabetes Overview. National Diabetes Information Clearinghouse [On-line information]. Available online at Accessed December 2009.

    (Updated 2009 November). Diabetes Mellitus. ARUP Consult [On-line information]. Available online at Accessed December 2009.

    Little, R. et. al. (2008 April 17). Standardization of C-Peptide Measurements. Clinical Chemistry. 2008;54:1023-1026. [On-line information]. Available online at Accessed December 2009.

    (Updated 2009 August). Insulinoma. ARUP Consult [On-line information]. Available online at . Accessed December 2009.

    Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, Pp 186-187.